[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646528":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":26,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":85,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Shanghai Mental Health Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active taVNS","EXPERIMENTAL","Intervention: Transcutaneous Auricular Vagus Nerve Stimulation Stimulation site: Left cymba conchae Frequency: 20 Hz Pulse width: 500 μs Intensity: 0.5-4 mA (perceptible but non-painful) Session duration: 40 minutes Frequency: 4 sessions\u002Fday Treatment course: 5 days (20 sessions)",[13],"Device: Transcutaneous Auricular Vagus Nerve Stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham taVNS","SHAM_COMPARATOR","Intervention: Sham Stimulation Site: Ipsilateral earlobe Same device appearance and parameters Minimal sensory stimulation without vagal activation Same treatment schedule as active group",[19],"Device: Sham Stimulation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Transcutaneous Auricular Vagus Nerve Stimulation","The stimulation duration is 40 minutes per session, administered four times daily for 5 consecutive days (20 sessions in total).",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sham Stimulation","Identical device appearance and parameters, with minimal sensory stimulation and no vagal activation. The treatment schedule is identical to that of the active group.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Jiang Du, M.D, Ph.D","CONTACT","+8618017311220","dujiangdou@163.com",[38],{"facility":5,"status":26,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Shanghai","Shanghai Municipality","200030","China","CN",{"type":45,"coordinates":46},"Point",[47,48],121.45806,31.22222,{"lat":48,"lon":47},[51],{"name":33,"role":34,"phone":52,"phoneExt":26,"email":36},"+86 021 6490 6315",{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100646528","the-efficacy-of-transcutaneous-auricular-vagus-nerve-stimulation-in-individuals-with-tiletamine-use-disorder-100646528",false,"NCT07689981","The Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation in Individuals With Tiletamine Use Disorder","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Tiletamine Use Disorder: A Randomized Double-Blind Sham-Controlled Trial","taVNS-Tiletami","Inclusion Criteria:\n\n* Age 18-60 years ≥6 years of education\\[7.1\\] DSM-5 diagnosis of substance use disorder related to tiletamine Tiletamine use ≥6 months and ≥1 time\u002Fweek Ability to provide informed consent Willingness to complete follow-up assessments\n\nExclusion Criteria:\n\n* Severe cognitive impairment History of epilepsy, brain injury, neurological disease or serious psychiatric disease Use of cognition-enhancing medications within 6 months Other psychoactive substance abuse within past 5 years (except nicotine) Metal implants in the head or severe skin sensitivity","ALL","18 Years","60 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"NA","Participants diagnosed with tiletamine use disorder will be assigned to active or sham taVNS for 5 days. Clinical outcomes ( e.g., behavioral paradigms measures and clinical scales ) and physiological markers (e.g., EEG and ECG) will be evaluated at baseline, post-treatment, and 3-month follow-ups to determine therapeutic efficacy and mechanisms of action.",[74,75,76],"Tiletamine Use Disorder","Substance Use Disorder (SUD)","Drug Craving",[78,79,80,81,82,83,76,84],"taVNS","Addiction","Brain-Heart Coupling","HRV","EEG","Neuromodulation","Tiletamine Dependence","NOT_YET_RECRUITING","2026-07-01",{"date":88,"type":89},"2026-07-08","ACTUAL",{"date":86,"type":68},{"date":92,"type":68},"2028-01-01",{"name":5,"class":6},1]